-+ 0.00%
-+ 0.00%
-+ 0.00%

InMed Pharmaceuticals Third Quarter 2025 Earnings: US$1.94 loss per share (vs US$3.58 loss in 3Q 2024)

Simply Wall St·05/15/2025 11:38:57
Listen to the news

InMed Pharmaceuticals (NASDAQ:INM) Third Quarter 2025 Results

Key Financial Results

  • Revenue: US$1.26m (up 7.6% from 3Q 2024).
  • Net loss: US$2.12m (loss widened by 23% from 3Q 2024).
  • US$1.94 loss per share.
Our free stock report includes 5 warning signs investors should be aware of before investing in InMed Pharmaceuticals. Read for free now.
earnings-and-revenue-history
NasdaqCM:INM Earnings and Revenue History May 15th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

InMed Pharmaceuticals shares are up 23% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with InMed Pharmaceuticals (at least 3 which shouldn't be ignored), and understanding these should be part of your investment process.